# Tolerability, Efficacy, and PK of ZSP1601 in Patients With Non-Alcoholic Steatohepatitis (NASH)

> **NCT04140123** · PHASE1,PHASE2 · COMPLETED · sponsor: **Guangdong Raynovent Biotech Co., Ltd** · enrollment: 37 (actual)

## Conditions studied

- Non-Alcoholic Steatohepatitis (NASH)

## Interventions

- **DRUG:** ZSP1601
- **DRUG:** ZSP1601 Placebo

## Key facts

- **NCT ID:** NCT04140123
- **Lead sponsor:** Guangdong Raynovent Biotech Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-06-23
- **Primary completion:** 2021-08-03
- **Final completion:** 2021-08-03
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2021-10-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04140123

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04140123, "Tolerability, Efficacy, and PK of ZSP1601 in Patients With Non-Alcoholic Steatohepatitis (NASH)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04140123. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*